What does this research mean for the field?

The Hemoglobin, Albumin, Lymphocyte, and Platelet (HALP) score is a promising biomarker for predicting short-term mortality in cardiovascular disease patients, but has limited predictive value for long-term mortality. Novelty: ClaimNovelty.SYNTHESIS. Consensus alignment: ConsensusAlignment.NEUTRAL.

What question did this study set out to answer?

The central aim is to evaluate the prognostic value of the HALP score in predicting long-term mortality in cardiovascular disease patients.

April 13, 2026

EXPRESS: Prognostic Value of the Hemoglobin, Albumin, Lymphocyte, and Platelet Score in Cardiovascular Disease: a systematic review and meta-analysis

Key Points

The central aim is to evaluate the prognostic value of the HALP score in predicting long-term mortality in cardiovascular disease patients.
Conducted a systematic review and meta-analysis of existing literature

Structured PICO

Does the HALP score predict short-term and long-term mortality in patients with cardiovascular disease?

Population

Patients with Cardiovascular Disease (CVD)

Intervention

Hemoglobin, Albumin, Lymphocyte, and Platelet (HALP) Score

Outcome

Short-term mortality (STM) and long-term mortalityhard clinical

The HALP score may serve as a useful prognostic biomarker for short-term mortality in cardiovascular disease, though its utility for predicting long-term mortality appears limited.

Abstract

HALP score shows promise as a biomarker for STM in CVD patients. However, its predictive value for long-term mortality is limited. Further research is needed to confirm its diagnostic accuracy and clinical utility for both mortality outcomes.

Bookmark

EXPRESS: Prognostic Value of the Hemoglobin, Albumin, Lymphocyte, and Platelet Score in Cardiovascular Disease: a systematic review and meta-analysis

Key Points

Structured PICO

Abstract

Cite This Study